Lemtrada Approval Status beta

  • FDA approved: No
  • Brand name: Lemtrada
  • Generic name: alemtuzumab
  • Company: Genzyme
  • Treatment for: Multiple Sclerosis

Lemtrada (alemtuzumab) is a monoclonal CD52 antibody in development for the treatment of relapsing multiple sclerosis.

FDA Approval Status for Lemtrada

DateArticle
Dec 30, 2013Genzyme Receives Complete Response Letter from FDA on Lemtrada (alemtuzumab) Application
Jan 28, 2013Genzyme's Lemtrada (alemtuzumab) Application for MS Accepted for Review by the FDA
Aug 27, 2012Genzyme Provides Update on U.S. Lemtrada Filing
Jun 12, 2012Genzyme Submits Applications to FDA and EMA for Approval of Lemtrada (alemtuzumab) for Multiple Sclerosis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Learn how medication, diet, and exercise are key to managing Multiple Sclerosis. Click Here

Close
Hide
(web2)